This article was originally published in The Tan Sheet
FDA's Anesthetic and Life Support Drugs Advisory Committee will hear a progress report on studies of the metabolism of lidocaine by human liver tissues on the second day of a June 9-10 meeting. FDA has been conducting studies on liver samples to determine if 2,6 xylidine, a lidocaine metabolite, is metabolized by humans; if not, the study would affirm the committee's August 1993 conclusion that studies showing development of nasal tumors in rats exposed to high doses of 2,6 xylidine are not relevant to humans ("The Tan Sheet" Aug. 30, 1993, p. 10). The meeting will convene in Conference Rooms D & E of FDA's Parklawn Building at 8 a.m. on June 10 and 8:30 a.m. on June 9
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC